Disulfiram: A Clinically Proven Deterrent for Alcohol Use Disorder
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.38 | $41.36 (0%) | 🛒 Add to cart |
| 60 | $1.11 | $82.73 $66.59 (20%) | 🛒 Add to cart |
| 90 | $1.02 | $124.09 $91.81 (26%) | 🛒 Add to cart |
| 120 | $0.98 | $165.46 $118.04 (29%) | 🛒 Add to cart |
| 180 | $0.94 | $248.19 $169.49 (32%) | 🛒 Add to cart |
| 270 | $0.91 | $372.28 $245.16 (34%) | 🛒 Add to cart |
| 360 | $0.89
Best per pill | $496.37 $319.82 (36%) | 🛒 Add to cart |
Synonyms | |||
Disulfiram is a cornerstone pharmacotherapeutic agent in the management of chronic alcohol use disorder (AUD). Its primary mechanism of action is not to reduce craving, but to create a powerful physiological aversion to alcohol consumption, thereby supporting long-term abstinence goals as part of a comprehensive treatment plan that includes counseling and psychosocial support. By inhibiting the enzyme aldehyde dehydrogenase, it causes an accumulation of acetaldehyde upon alcohol ingestion, producing a highly unpleasant and memorable reaction. This guide provides a detailed, expert overview for healthcare professionals and informed patients on its use, ensuring safe and effective application.
Features
- Pharmacological Class: Aldehyde dehydrogenase inhibitor.
- Mechanism of Action: Produces acute sensitivity to ethanol by inhibiting its normal metabolic breakdown, leading to a rapid increase in blood acetaldehyde concentration.
- Bioavailability: Readily absorbed from the gastrointestinal tract following oral administration, though it can undergo slow and incomplete absorption.
- Metabolism: Extensively reduced in the liver to diethyldithiocarbamate, which is then metabolized to carbon disulfide, a compound also found in the breath of patients.
- Elimination: Primarily eliminated via metabolism; only a small portion is excreted unchanged in urine.
- Onset of Action: The enzyme-inhibiting effect begins within 1-2 hours of ingestion and lasts for a significant period, often up to 14 days after the last dose due to irreversible enzyme inhibition.
- Formulation: Standard oral tablets (250 mg and 500 mg).
Benefits
- Creates a Powerful Psychological Deterrent: The knowledge of the potential disulfiram-ethanol reaction (DER) serves as a strong psychological barrier against impulsive alcohol consumption, reinforcing commitment to sobriety.
- Supports Structured Recovery Programs: Functions most effectively as an adherence tool within a broader multimodal treatment framework, including cognitive behavioral therapy and support groups.
- Provides a Clear Cause-and-Effect Consequence: Offers patients a tangible and immediate negative consequence for alcohol use, which can be a crucial tool for those who struggle with the abstract long-term harms of AUD.
- Non-Narcotic and Non-Addictive: Does not possess abuse potential or produce euphoria, making it a safe choice from a dependency standpoint.
- Enables Patient Empowerment: By taking the medication daily, patients actively participate in their treatment plan, fostering a sense of control and responsibility over their recovery.
Common use
Disulfiram is indicated as an adjunctive therapy in the management of selected patients seeking to maintain abstinence from alcohol while undergoing concurrent psychosocial support and counseling. It is not a cure for alcoholism and does not treat the underlying pathophysiology of addiction or reduce the craving for alcohol. Its use is predicated on the patient’s full knowledge of the consequences of alcohol consumption while on the drug and their voluntary commitment to abstinence. It is typically prescribed for patients in a stable medical and psychiatric condition who are highly motivated and under supervision.
Dosage and direction
Dosage must be individualized under strict medical supervision. Treatment should not be initiated until the patient has abstained from alcohol for at least 12 hours and a baseline transaminase level has been established.
- Initial Dosage: A maximum of 500 mg daily is administered orally as a single dose for the first one to two weeks.
- Maintenance Dosage: The daily dosage can usually be reduced to 250 mg (125 mg to 500 mg ranges are used). The lower end of the dosage range may be equally effective for aversion while potentially minimizing daily side effects.
- Administration: The tablet can be crushed and mixed with liquid if needed. It is typically taken in the morning, as the temptation to drink may be higher in the evening.
- Duration of Therapy: The duration of therapy is highly individualized and may continue for months or even years until the patient is fully established in a recovery lifestyle. The decision to discontinue should be made collaboratively with the treating physician.
- Supervised Administration: For optimal efficacy, especially in the initial phases, administration should be supervised by a family member, caregiver, or healthcare professional to ensure adherence.
Precautions
- Informed Consent: The patient must be fully informed, comprehend, and consent to the therapy and the dangers of the alcohol reaction. Written consent is often advisable.
- Hepatotoxicity: Disulfiram has been associated with life-threatening hepatitis and hepatic failure. Baseline liver function tests (LFTs) must be performed and monitored regularly (e.g., every 2-4 weeks for the first 6 months, then periodically thereafter).
- Psychosis: In rare instances, disulfiram has been associated with the development of psychotic reactions, including paranoia, mania, and schizophrenia-like symptoms, often in patients with a pre-existing history of psychiatric disorders.
- Peripheral Neuropathy: Long-term use has been linked to peripheral neuritis, presenting as numbness or tingling in the extremities. This is potentially due to carbon disulfide metabolites and may be reversible upon discontinuation.
- Occupational Hazards: Patients should be cautioned that disulfiram can impair their ability to engage in hazardous activities (e.g., operating machinery, driving) until their response to the drug is known, primarily due to sedative effects.
- Pregnancy and Lactation: Disulfiram should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not recommended for nursing mothers.
Contraindications
Disulfiram is absolutely contraindicated in the presence of the following conditions:
- Severe myocardial disease or coronary occlusion.
- Psychosis (current or severe history).
- Hypersensitivity to disulfiram or other thiuram derivatives used in pesticides and rubber vulcanization.
- Concurrent use of alcohol or alcohol-containing preparations (e.g., elixirs, tonics, sauces, vinegars, aftershaves, liniments).
- Concurrent use of metronidazole, paraldehyde, or other agents that may produce disulfiram-like reactions.
- Severe hepatic impairment or baseline transaminase levels more than 2-3 times the upper limit of normal.
Possible side effect
The following adverse reactions, distinct from the intentional disulfiram-ethanol reaction, may occur:
- Common (≥1/100): Drowsiness, fatigue, headache, metallic or garlic-like aftertaste, acneiform eruptions, allergic dermatitis.
- Uncommon (≥1/1,000 to <1/100): Impotence, peripheral neuropathy, optic neuritis, polyneuritis, hepatotoxicity (manifesting as jaundice, dark urine, clay-colored stools, anorexia, abdominal pain).
- Rare (<1/1,000): Psychotic episodes, depression, confusion, memory impairment, catatonia, seizures, hepatitis (fulminant and potentially fatal).
Drug interaction
Disulfiram inhibits several hepatic microsomal enzymes, leading to numerous significant interactions:
- Warfarin: Potentiates anticoagulant effect by inhibiting its metabolism; prothrombin time must be monitored closely and warfarin dosage reduced.
- Phenytoin: Significantly increases phenytoin plasma levels, increasing the risk of phenytoin toxicity (nystagmus, ataxia, lethargy); phenytoin levels must be monitored.
- Benzodiazepines: May increase the levels and sedative effects of certain benzodiazepines (e.g., chlordiazepoxide, diazepam) that are metabolized by CYP pathways.
- Tricyclic Antidepressants: Metabolism of imipramine and desipramine can be inhibited.
- Theophylline: May inhibit the metabolism of theophylline, increasing the risk of toxicity.
- Isoniazid: Concurrent use may unbalance coordination or produce dizziness and should be avoided.
- CNS Depressants: Additive sedative effects with barbiturates and other sedative-hypnotics.
Missed dose
- If a dose is missed, it should be taken as soon as remembered on the same day.
- If the day has passed, the patient should skip the missed dose and resume the usual dosing schedule the next day.
- Do not double the dose to make up for a missed one.
- Maintaining the regular schedule is critical for continuous enzyme inhibition. A lapse of several days may require re-initiation of therapy under medical supervision.
Overdose
Symptoms of overdose are primarily neurological and may include nausea, vomiting, dizziness, ataxia, seizures, lethargy, and coma. In severe cases, electrocardiogram changes and cardiovascular collapse may occur. There is no specific antidote. Management consists of supportive and symptomatic measures, including gastric lavage if presented early, and maintaining adequate respiration and circulatory function. Hemodialysis is not likely to be effective due to high protein binding and large volume of distribution.
Storage
- Store at controlled room temperature, 20°C to 25°C (68°F to 77°F).
- Keep in a tightly closed, light-resistant container as specified by the manufacturer.
- Keep out of reach of children and pets.
- Do not use after the expiration date printed on the packaging.
Disclaimer
This information is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The author and publisher are not responsible for any errors or omissions or for any consequences from the application of this information.
Reviews
- Clinical Efficacy (4.2/5): “Disulfiram remains a gold-standard deterrent therapy. Its efficacy is almost entirely dependent on patient adherence and motivation. In a supervised setting, it is an incredibly powerful tool for enforcing abstinence and breaking the cycle of relapse.” – Addiction Psychiatrist, 15 years experience.
- Safety Profile (3.5/5): “A necessary but demanding drug. The hepatotoxicity risk requires vigilant, lifelong monitoring. We only initiate after thorough screening and with a highly committed patient. The side effects can be significant, but the benefit of sustained sobriety often outweighs them.” – Hepatologist.
- Patient Experience (4.0/5): “It gave me the ‘fence’ I needed in early recovery. Knowing the severe consequence of a drink removed the option entirely, which was a relief. The metallic taste was bothersome but a small price to pay for my life back.” – Patient, 3 years sober.
- Utility in Practice (3.8/5): “Not a first-line drug for everyone, but for the right patient, it’s irreplaceable. It functions as a behavioral contract in pill form. The key is proper patient selection and comprehensive education about the disulfiram side effects and the ethanol reaction.” – General Practitioner.